On air · 1 of 3 networks
Antidote Technologies
- antidote.me
- Healthcare & Life Sciences
- US
- 23 employees
Antidote Technologies’s ads on LinkedIn, Meta and Google, recorded by adsrunning. Browse the latest here for free. Sign up free to see all 23. Watch Antidote Technologies with Starter to get each new one in your feed.
Watchlist with Starter · $49/mo
| Network | Status | Live ads | Nov 2025LinkedIn activity · 52 weeksNov 2026 | Checked | Next step |
|---|---|---|---|---|---|
| Running | 23 | Checked 30 Oct 2026 | See all 23 ads → | ||
| Meta | None recorded | 0 | No active ads recorded on the Meta Ad Library | Checked 17 Oct 2026 | Collect them with the API → |
| None recorded | 0 | No ads found on the Google Ads Transparency Center | Checked 3 Oct 2026 | Collect them with the API → |
Antidote Technologies has 23 live LinkedIn ads. Its Facebook page had no active ads on 17 Oct 2026, and we recorded no Google ads on 3 Oct 2026.
Latest ads
- LINKEDIN · IMAGERecorded 7 Sept 2026
One BMI cutoff ruled out 37% of candidates in a sleep apnea study. (Antidote, 2026, n=95) One eligibility line, set before anyone tested it against real patients. Download the report to see where four more studies lost their qualification number.
- LINKEDIN · IMAGERecorded 7 Sept 2026
Recruiting for a Parkinson's disease clinical trial and worried your enrollment number won't hold? In one feasibility study, 214 patients raised their hand. A single narrow requirement left only 9 who met the eligibility criteria. (Antidote, 2026, n=214) Antidote's Market Feasibility Test (MFT) puts your eligibility criteria in front of real patients before enrollment begins, so you can uncover patient recruitment barriers while there is still time to fix them. See the same test run across five studies. Get Exclusive Access to the Feasibility Report
- LINKEDIN · IMAGERecorded 7 Sept 2026
Confident your diagnosis pool will convert into qualified enrollees? In one heart failure study, interest was high — yet only 2 of 26 patients qualified. (Antidote, 2026, n=26) Antidote's Market Feasibility Test (MFT) puts your eligibility criteria in front of real patients before enrollment begins, revealing the gap between who's interested and who actually qualifies. Download the report to see the gap across five studies.
- LINKEDIN · IMAGERecorded 7 Sept 2026
A diagnosis rate is not an enrollment rate. In one heart failure study, 59% said they had the condition. 2 of 26 qualified for the trial. On paper the population looked ready. The criteria found a different number. Tested. What's your number?
- LINKEDIN · IMAGERecorded 7 Sept 2026
One line in a trial protocol ruled out 37% of candidates. A single BMI cutoff, set before anyone tested it against real patients. That is what happens when protocol criteria are written before there is any proof of the audience. A Market Feasibility Test surfaces the friction before your protocol reaches clinical sites. What's your number? Download the Full Data Brief Now for Free
- LINKEDIN · IMAGERecorded 7 Sept 2026
Interest is not eligibility. In one Parkinson's disease feasibility study, 214 people responded. Only 9 met the trial's eligibility criteria. The willingness was there. A single narrow requirement decided the rest. That gap is exactly what a Market Feasibility Test surfaces before your protocol reaches clinical sites. What's your number? Get Exclusive Access to the Data Brief
6 of 23 adsSign up to see every Antidote Technologies ad, filter by format and date, and get alerts on new ones.
See all 23 adsWatch the companies you care about.
Filter every ad by industry, country, format and network, and get alerts when a company you watch starts running new ads.